- Home
- CRSR vs LBRX Comparison
CRSR vs LBRX Comparison
Compare CRSR & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSR | LBRX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.8M | 563.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRSR | LBRX |
|---|---|---|
| Price | $4.75 | $23.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $9.75 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 1.1M | 205.3K |
| Earning Date | 02-12-2026 | 06-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,449,248,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.79 | N/A |
| 52 Week Low | $4.59 | $13.36 |
| 52 Week High | $13.02 | $24.95 |
Technical Indicators
Market Signals| Indicator | CRSR | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 60.99 |
| Support Level | $4.59 | $20.65 |
| Resistance Level | $5.29 | $24.95 |
| Average True Range (ATR) | 0.21 | 1.85 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 19.82 | 89.58 |
Price Performance
Historical ComparisonAbout CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.